Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation

Toxins (Basel). 2018 Jun 5;10(6):229. doi: 10.3390/toxins10060229.

Abstract

Non-transplanted and transplanted patients with chronic kidney disease (CKD) differ in terms of mortality and the risk of clinical events. This difference is probably due to the difference of both traditional and non-traditional risk factors. Uremic retention solutes may constitute important non-traditional risk factors in this population. In the present review, we selected a set of uremic toxins that have been associated with harmful effects, and are an appealing target for adjuvant therapy in CKD. For each toxin reviewed here, relevant studies were selected and the relationship with hard clinical outcomes of uremic toxins were compared between non-transplanted CKD patients and transplanted patients taking into account the level of glomerular filtration rate in these two situations.

Keywords: chronic kidney disease; outcomes; renal transplantation; uremic toxins.

Publication types

  • Review

MeSH terms

  • Animals
  • Fibroblast Growth Factor-23
  • Fibroblast Growth Factors / blood
  • Humans
  • Kidney Transplantation
  • Methylamines / blood
  • Phosphates / blood
  • Toxins, Biological / blood*
  • Treatment Outcome
  • Uremia / blood*

Substances

  • Methylamines
  • Phosphates
  • Toxins, Biological
  • Fibroblast Growth Factors
  • Fibroblast Growth Factor-23
  • trimethyloxamine